alzheon, Author at Alzheon | Preserving Future Memories - Page 16 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 208 blog entries.

24 Apr, 2017

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data

alzheon2019-09-23T12:10:49-04:00April 24th, 2017|

30 Mar, 2017

Alzheon Presents Data to Support Selection of Patients with Mild Alzheimer’s Disease for Pivotal Study of ALZ-801 Using Precision Medicine Approach

alzheon2024-08-12T10:30:44-04:00March 30th, 2017|

29 Mar, 2017

ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

29 Mar, 2017

Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

13 Feb, 2017

Alzheon to Present New Clinical Data and Analyses for ALZ-801 and its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases

alzheon2024-08-09T11:50:12-04:00February 13th, 2017|

13 Feb, 2017

Alzheon Appoints Neil Flanzraich, JD, as Chief Business Officer

alzheon2020-06-26T16:57:23-04:00February 13th, 2017|

4 Jan, 2017

Alzheon Appoints Nobel Laureate Stanley B. Prusiner, MD, as Chair of Scientific Advisory Board

alzheon2020-06-26T16:56:47-04:00January 4th, 2017|

9 Dec, 2016

Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program

alzheon2019-09-23T12:10:50-04:00December 9th, 2016|

9 Dec, 2016

Alzheon Presents Analyses from Phase 3 Clinical Studies Showing Largest Clinical Effects of Tramiprosate, the Active Molecule of ALZ-801, in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease

alzheon2020-06-26T17:00:01-04:00December 9th, 2016|

21 Nov, 2016

Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th Clinical Trials on Alzheimer’s Disease Congress

alzheon2020-06-26T16:56:24-04:00November 21st, 2016|